PREMISE: European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor
Astellas Pharma Europe Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT02495974
Collaborator
Medivation, Inc. (Industry)
1,763
182
41
9.7
0.2
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Observational
Actual Enrollment
:
1763 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Actual Study Start Date
:
Sep 8, 2015
Actual Primary Completion Date
:
Feb 8, 2019
Actual Study Completion Date
:
Feb 8, 2019
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with mCRPC prescribed enzalutamide Oral |
Drug: enzalutamide
oral
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time to treatment failure (TTF) [up to 18 months]
Time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.
Secondary Outcome Measures
- Time to prostate specific antigen (PSA) progression [up to 18 months]
Time from initiation of enzalutamide to the date of PSA progression. PSA progression is defined as a PSA rise of greater than or equal to 25% and an absolute increase of greater than or equal to 2 ng/mL.
- PSA response [up to 18 months]
- Time to disease progression [up to 18 months]
Time from initiation of enzalutamide to the date of radiographic progression, PSA progression or clinical progression according to the investigator's assessment.
- Overall Survival (France only) [up to 18 months]
Time from initiation of enzalutamide to death or patient survival at the end of the study.
- Treatment duration [up to 18 months]
- Reason for initiation of treatment with enzalutamide [up to 18 months]
- Reason for enzalutamide discontinuation [up to 18 months]
- Subsequent anti-neoplastic therapy for mCRPC [up to 18 months]
- Time to opiate use [up to 18 months]
- Pain assessed by Brief Pain Inventory Short Form (BPI-SF) [up to 18 months]
The questionnaire is a patient self-rating scale assessing the level of pain, effect of the pain on activities of daily living, and analgesic use.
- Quality of life of participants assessed using EQ-5D-5L [up to 18 months]
EuroQol5 dimension 5 level health state utility index - 5L (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. It is designed for self-completion by respondents comprising the following dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
- Quality of life of participants assessed using FACT-P [up to 18 months]
Functional Assessment of Cancer Therapy - Prostate (FACT-P) is a self reported instrument designed to assess patient function in physical, social/family, emotional, and functional well-being and further assesses items for prostate-related symptoms.
- Number of participants hospitalized [up to 18 months]
- Number of visits to health care professionals [up to 18 months]
- Safety assessed by reported adverse events [up to 18 months]
- Safety assessed by modification of treatment with enzalutamide as a response to adverse events [up to 18 months]
- Number of Deaths [up to 18 months]
Deaths defined as deaths due to any cause
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Men with mCRPC who have been prescribed enzalutamide as part of standard clinical practice
-
Germany only: Enzalutamide will be prescribed according to the current SmPC (Summary of Product Characteristics)
Exclusion Criteria:
-
Patients with the following will be excluded from study participation in France only:
-
Patients who have previously been treated with abiraterone acetate (Zytiga®) after docetaxel chemotherapy.
-
Patients who have previously been treated with cabazitaxel (Jevtana®)
-
Patients who have previously been treated with Xtandi®
-
Patients taking part in an interventional clinical trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Site AT43001 | Bregenz | Austria | 6900 | |
| 2 | Site AT43005 | Innsbruck | Austria | 6020 | |
| 3 | Site AT43006 | Linz | Austria | 4010 | |
| 4 | Site AT43004 | Wien | Austria | 1090 | |
| 5 | Site BL32003 | Bonheiden | Antwerpen | Belgium | 2820 |
| 6 | Site BL32004 | Brasschaat | Antwerpen | Belgium | 2930 |
| 7 | Site BL32007 | Haine-Saint-Paul | Hainaut | Belgium | 7100 |
| 8 | Site BL32008 | Aalst | Oost-Vlaanderen | Belgium | 9300 |
| 9 | Site BL32009 | Gent | Oost-Vlaanderen | Belgium | 9000 |
| 10 | Site BL32010 | Sint-Niklaas | Oost-Vlaanderen | Belgium | 9100 |
| 11 | Site BL32013 | Leuven | Vlaams Brabant | Belgium | 3000 |
| 12 | Site BL32005 | Kortrijk | West-Vlaanderen | Belgium | 8500 |
| 13 | Site BL32001 | Brussels | Belgium | 1070 | |
| 14 | Site BL32011 | Bruxelles | Belgium | 1200 | |
| 15 | Site BL32012 | Hasselt | Belgium | 3500 | |
| 16 | Site BG35903 | Plovdiv | Bulgaria | 4000 | |
| 17 | Site BG35901 | Sofia | Bulgaria | 1303 | |
| 18 | Site CZ42004 | Brno | Czechia | 656 91 | |
| 19 | Site CZ42007 | Jihlava | Czechia | 586 33 | |
| 20 | Site CZ42003 | Novy Jicin | Czechia | 741 01 | |
| 21 | Site CZ42001 | Praha | Czechia | 140 59 | |
| 22 | Site CZ42006 | Praha | Czechia | 180 81 | |
| 23 | Site DK45003 | Aalborg | Denmark | 9100 | |
| 24 | Site DK45004 | Aarhus | Denmark | 8000 | |
| 25 | Site DK45002 | Copenhagen | Denmark | 2200 | |
| 26 | Site DK45001 | Herlev | Denmark | 2730 | |
| 27 | Site FR33015 | Colmar | Alsace | France | 68024 |
| 28 | Site FR33003 | Strasbourg | Alsace | France | 67000 |
| 29 | Site FR33017 | Bordeaux | Aquitaine | France | 33000 |
| 30 | Site FR33051 | Bordeaux | Aquitaine | France | 33000 |
| 31 | Site FR33018 | Bordeaux | Aquitaine | France | 33300 |
| 32 | Site FR33022 | Clermont Ferrand | Auvergne | France | 63100 |
| 33 | Site FR33006 | Aix en Provence | Bouches-du-Rhône | France | 13617 |
| 34 | Site FR33027 | Marseille | Bouches-du-Rhône | France | 13005 |
| 35 | Site FR33041 | Marseille | Bouches-du-Rhône | France | 13286 |
| 36 | Site FR33069 | Saint-Martin-Boulogne | Boulogne-sur-Mer | France | 62222 |
| 37 | Site FR33043 | Sens | Bourgogne | France | 89100 |
| 38 | Site FR33026 | Brest Cedex 2 | Bretagne | France | 29229 |
| 39 | Site FR33004 | Saint Grégoire | Bretagne | France | 35760 |
| 40 | Site FR33025 | Vannes | Bretagne | France | 56000 |
| 41 | Site FR33010 | Reims Cedex | Champagne-Ardenne | France | 51726 |
| 42 | Site FR33067 | Dijon | Côte-d'Or | France | 21000 |
| 43 | Site FR33062 | Longjumeau | Essonne | France | 91164 |
| 44 | Site FR33033 | Evreux | Eure | France | 27000 |
| 45 | Site FR33002 | Quimper | Finistère | France | 29000 |
| 46 | Site FR33040 | Toulouse | Haute-Garonne | France | 31059 |
| 47 | Site FR33049 | Gap | Hautes-Alpes | France | 05000 |
| 48 | Site FR33042 | Suresnes | Hauts-de-Seine | France | 92151 |
| 49 | Site FR33020 | Tours | Indre-et-Loire | France | 37044 |
| 50 | Site FR33060 | Grenoble | Isère | France | 38043 |
| 51 | Site FR33050 | Bézier | Languedoc-Roussillon | France | 34500 |
| 52 | Site FR33066 | Orléans | Loiret | France | 45067 |
| 53 | Site FR33016 | Saint-Priest-en-Jarez | Loire | France | 42271 |
| 54 | Site FR33061 | Vandœuvre-lès-Nancy | Lorraine | France | 54519 |
| 55 | Site FR33065 | Agen | Lot-et-Garonne | France | 47000 |
| 56 | Site FR33019 | Angers | Maine-et-Loire | France | 49933 |
| 57 | Site FR33007 | Nancy | Meurthe-et-Moselle | France | 54000 |
| 58 | Site FR33059 | Albi | Midi-Pyrénées | France | 81000 |
| 59 | Site FR33039 | Lille | Nord-Pas-de-Calais | France | 59037 |
| 60 | Site FR33021 | Coudekerque-Branche Cedex | Nord | France | 59210 |
| 61 | Site FR33063 | Beauvais | Oise | France | 60000 |
| 62 | Site FR33070 | Amiens | Picardie | France | 80094 |
| 63 | Site FR33044 | Saint Quentin Cedex | Picardie | France | 02321 |
| 64 | Site FR33028 | Clermont Ferrand Cedex 1 | Puy-de-Dôme | France | 63003 |
| 65 | Site FR33035 | Bayonne | Pyrénées-Atlantiques | France | 64100 |
| 66 | Site FR33009 | Valence | Rhône-Alpes | France | 26000 |
| 67 | Site FR33012 | Lyon Cedex 9 | Rhône | France | 69009 |
| 68 | Site FR33030 | Lyon | Rhône | France | 69437 |
| 69 | Site FR33058 | Chalon-Sus-Saone | Saône-et-Loire | France | 71100 |
| 70 | Site FR33008 | Amiens | Somme | France | 80000 |
| 71 | Site FR33032 | Amiens | Somme | France | 80090 |
| 72 | Site FR33014 | Créteil | Val-de-Marne | France | 94400 |
| 73 | Site FR33037 | Saint Mandé | Val-de-Marne | France | 94160 |
| 74 | Site FR33011 | Toulon | Var | France | 83100 |
| 75 | Site FR33001 | Avignon Cedex 9 | Vaucluse | France | 84918 |
| 76 | Site FR33046 | Arras | France | 62660 | |
| 77 | Site FR33054 | Hyères | France | 83400 | |
| 78 | Site FR33038 | La Chaussée-Saint-Victor | France | 41260 | |
| 79 | Site FR33057 | Paris | France | 75014 | |
| 80 | Site FR33034 | Paris | France | 75020 | |
| 81 | Site FR33029 | Paris | France | 75475 | |
| 82 | Site FR33064 | Paris | France | 75908 | |
| 83 | Site DE49001 | Nürtingen | Baden-Württemberg | Germany | 72622 |
| 84 | Site DE49016 | Wiesbaden | Hessen | Germany | 65191 |
| 85 | Site DE49003 | Lüneburg | Niedersachsen | Germany | 21335 |
| 86 | Site DE49011 | Soltau | Niedersachsen | Germany | 29614 |
| 87 | Site DE49013 | Bonn | Nordrhein-Westfalen | Germany | 53111 |
| 88 | Site DE49009 | Bernburg | Sachsen-Anhalt | Germany | 06406 |
| 89 | Site DE49012 | Chemnitz | Sachsen | Germany | 09130 |
| 90 | Site DE49015 | Kiel | Schleswig-Holstein | Germany | 24103 |
| 91 | Site DE49005 | Köln | Germany | 50968 | |
| 92 | Site DE49006 | Rostock | Germany | 18107 | |
| 93 | Site DE49014 | Wuppertal | Germany | 42103 | |
| 94 | Site DE49010 | Würselen | Germany | 52146 | |
| 95 | Site GC30001 | Kifisia | Attiki | Greece | 14564 |
| 96 | Site GC30013 | Athens | Greece | 11528 | |
| 97 | Site GC30007 | Athens | Greece | 45001 | |
| 98 | Site GC30005 | Athens | Greece | 45500 | |
| 99 | Site GC30010 | Athens | Greece | 54642 | |
| 100 | Site GC30003 | Athens | Greece | 57001 | |
| 101 | Site GC30004 | Ioannina | Greece | 11525 | |
| 102 | Site GC30006 | Ioannina | Greece | 15126 | |
| 103 | Site GC30012 | Larissa | Greece | 41110 | |
| 104 | Site GC30008 | Thessaloniki | Greece | 11522 | |
| 105 | Site GC30002 | Thessaloniki | Greece | 14564 | |
| 106 | Site GC30011 | Thessaloniki | Greece | 56403 | |
| 107 | Site HU36006 | Debrecen | Hajdú-Bihar | Hungary | 4032 |
| 108 | Site HU36002 | Budapest | Hungary | 1082 | |
| 109 | Site HU36001 | Budapest | Hungary | 1122 | |
| 110 | Site HU36005 | Szeged | Hungary | H-6720 | |
| 111 | Site HU36003 | Szombathely | Hungary | H-9700 | |
| 112 | Site IR35304 | Dublin | Ireland | 24 | |
| 113 | Site IR35302 | Dublin | Ireland | 7 | |
| 114 | Site IR35305 | Dublin | Ireland | 7 | |
| 115 | Site IR35306 | Dublin | Ireland | 8 | |
| 116 | Site IT39001 | Meldola | Forlì | Italy | 47014 |
| 117 | Site IT39010 | Lecco | Lombardia | Italy | 23900 |
| 118 | Site IT39009 | Rozzano | Milano | Italy | 20089 |
| 119 | Site IT39002 | Aviano | Pordenone | Italy | 33081 |
| 120 | Site IT39013 | Candiolo | Torino | Italy | 10060 |
| 121 | Site IT39011 | Mirano | Venezia | Italy | 30035 |
| 122 | Site IT39005 | Bari | Italy | 70124 | |
| 123 | Site IT39012 | Catania | Italy | 95122 | |
| 124 | Site IT39006 | Firenze | Italy | 50134 | |
| 125 | Site IT39004 | Milano | Italy | 20141 | |
| 126 | Site IT39017 | Milano | Italy | 20162 | |
| 127 | Site IT39003 | Modena | Italy | 41124 | |
| 128 | Site IT39007 | Napoli | Italy | 80131 | |
| 129 | Site IT39018 | Novara | Italy | 28100 | |
| 130 | Site IT39008 | Padova | Italy | 35128 | |
| 131 | Site IT39015 | Palermo | Italy | 90146 | |
| 132 | Site IT39014 | Pisa | Italy | 56126 | |
| 133 | Site IT39016 | Reggio Emilia | Italy | 42100 | |
| 134 | Site NL31006 | Arnhem | Netherlands | 6815 AD | |
| 135 | Site NL31007 | Breda | Netherlands | 4819 EV | |
| 136 | Site NL31003 | Den Haag | Netherlands | 2545 CH | |
| 137 | Site NL31005 | Doetinchem | Netherlands | 7009 BL | |
| 138 | Site NL31008 | Helmond | Netherlands | 5707 HA | |
| 139 | Site NL31001 | Hilversum | Netherlands | 1213 XZ | |
| 140 | Site NL31004 | Hoofddorp | Netherlands | 2134 TM | |
| 141 | Site NL31010 | Nieuwegein | Netherlands | 3435 CM | |
| 142 | Site NL31011 | Zwolle | Netherlands | 8025 AB | |
| 143 | Site PT35101 | Porto | Portugal | 4099-001 | |
| 144 | Site SV38501 | Ljubljana | Slovenia | ||
| 145 | Site ES34007 | Zaragoza | Aragón | Spain | 50009 |
| 146 | Site ES34012 | Zaragoza | Aragón | Spain | 50009 |
| 147 | Site ES34008 | Guadalajara | Castilla La Mancha | Spain | 19002 |
| 148 | Site ES34009 | Toledo | Castilla La Mancha | Spain | 45004 |
| 149 | Site ES34013 | Barcelona | Cataluña | Spain | 08036 |
| 150 | Site ES34011 | Lleida | Cataluña | Spain | 25198 |
| 151 | Site ES34010 | Reus | Cataluña | Spain | 43204 |
| 152 | Site ES34004 | Badajoz | Extremadura | Spain | 06002 |
| 153 | Site ES34006 | Cáceres | Extremadura | Spain | 10003 |
| 154 | Site ES34005 | A Coruña | Galicia | Spain | 15006 |
| 155 | Site ES34016 | Lugo | Galicia | Spain | 27003 |
| 156 | Site ES34003 | Orense | Galicia | Spain | 32005 |
| 157 | Site ES34001 | Santiago de Compostela | Galicia | Spain | 15706 |
| 158 | Site ES34017 | Vigo | Galicia | Spain | 36312 |
| 159 | Site GB44001 | Aberdeen | Aberdeenshire | United Kingdom | AB25 2ZN |
| 160 | Site GB44012 | Torquay | Devon | United Kingdom | TQ2 7AA |
| 161 | Site GB44025 | Poole | Dorset | United Kingdom | BH15 2JB |
| 162 | Site GB44026 | Blackburn | Lancashire | United Kingdom | BB2 3HH |
| 163 | Site GB44011 | Preston | Lancashire | United Kingdom | PR2 9HT |
| 164 | Site GB44004 | Boston | Lincolnshire | United Kingdom | PE21 9QS |
| 165 | Site GB44002 | Lincoln | Lincolnshire | United Kingdom | LN2 5QY |
| 166 | Site GB44008 | Berkshire | Slough | United Kingdom | SL2 4HL |
| 167 | Site GB44013 | Weston-super-Mare | Somerset | United Kingdom | BS23 4TQ |
| 168 | Site GB44007 | Treliske | Truro | United Kingdom | TR1 3LJ |
| 169 | Site GB44009 | Swindon | Wiltshire | United Kingdom | SN3 6BB |
| 170 | Site GB44005 | Worcester | Worcestershire | United Kingdom | WR5 1DD |
| 171 | Site GB44023 | Birmingham | United Kingdom | B15 2TH | |
| 172 | Site GB44010 | Brighton | United Kingdom | BN2 3EW | |
| 173 | Site GB44016 | Derby | United Kingdom | DE22 3NE | |
| 174 | Site GB44020 | Guildford | United Kingdom | GU2 7XX | |
| 175 | Site GB44022 | Inverness-shire | United Kingdom | IV2 3UJ | |
| 176 | Site GB44024 | Leicester | United Kingdom | LE1 5WW | |
| 177 | Site GB44003 | London | United Kingdom | NW1 2BU | |
| 178 | Site GB44017 | Newcastle upon Tyne | United Kingdom | NE7 7DN | |
| 179 | Site GB44015 | Norfolk | United Kingdom | PE30 4ET | |
| 180 | Site GB44006 | Reading | United Kingdom | RG1 5AN | |
| 181 | Site GB44014 | Taunton | United Kingdom | TA1 5DA | |
| 182 | Site GB44018 | Wolverhampton | United Kingdom | WV10 0QP |
Sponsors and Collaborators
- Astellas Pharma Europe Ltd.
- Medivation, Inc.
Investigators
- Study Director: Clinical Research Physician, Astellas Pharma Europe Ltd.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Astellas Pharma Europe Ltd.
ClinicalTrials.gov Identifier:
NCT02495974
Other Study ID Numbers:
- 9785-MA-1002
First Posted:
Jul 13, 2015
Last Update Posted:
May 1, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Astellas Pharma Europe Ltd.
Additional relevant MeSH terms: